{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}

Red Flags Detected

  • Delisting (new) — Company received Nasdaq non-compliance notices in 2025 for failing to meet minimum stockholders' equity and bid price requirements, though compliance was later regained.
NASDAQ: MBRX Moleculin Biotech, Inc. 10-Q

Moleculin omits controls disclosure, faces Nasdaq delisting risk after 2025 compliance lapses

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MBRX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 27, 2026 1:35 AM